Grace Therapeutics, Inc.

US$1.85As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:GRCEHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (29.82%)
Div yield —
ROE (36.19%)
Biotechnology
Beta (5Y) 0.41
PE TTM —
TSR TTM (41.36%)
Mkt cap US$38.92M
ROIC (11.60%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.78
(3.65%)
(71.26%)
Hold 11|0|2|5|1
3Q26
4Q26
1Q27
2Q27
Earnings per share$
0.03
0.03
0.03
0.03
(9.08%)
(8.67%)
(1.49%)
11.31%
Revenue$M
4.195
4.435
4.462
4.385
4.34%
8.85%
6.58%
6.65%
Peers (US$38.92M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.899
0.239
0.227
EBIT/Intx
0.183
0.285
0.264
Own earn%
100.69
(18.76)
(20.26)
Sh yield%
36.86
24.83
21.16
Owners
Insiders/Inst%
9.12
84.20
Short interest%
4.14
SBC / revenue%
4.38
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
11–17
$1 testx
0.1
Incr. ROIC%
2